Future Research With Car T-Cell Therapy in Multiple Myeloma: Adam Sperling, MD, PhD


The physician at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School discussed future research with CAR T-cell therapy in multiple myeloma.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Adam Sperling, MD, PhD, a physician at the Dana-Farber Cancer Institute, and an instructor in medicine at Harvard Medical School, about future research with CAR T-cell therapy in multiple myeloma.

Sperling discussed randomized phase 3 studies of idecabtagene vicleucel (ide-cel; Abecma) and ciltacabtagene autoleucel (cilta-cel) compared with standard-of-care therapies in relapsed/refractory multiple myeloma are ongoing. Although no data are yet available, it is likely that CAR T-cell therapies will outperform standard therapies in this setting, Sperling adds.

Additionally, CAR T-cell therapy is being evaluated in earlier lines of treatment for patients with multiple myeloma, Sperling says. The products may have utility in high-risk patients who progress following first-line treatment, or as an option after or instead of stem cell transplant, Sperling says. Combination strategies with CAR T-cell therapy are also emerging to determine whether patients can achieve deeper and more durable responses, Sperling explains.

Finally, ongoing research efforts are focused on understanding and overcoming mechanisms of resistance to CAR T-cell therapy, Sperling says. Dual-targeting CAR T-cell therapies or combination approaches with CAR T-cell therapy and agents, such as gamma secretase inhibitors, may be useful in combatting resistance to CAR T-cell therapy in multiple myeloma, concludes Sperling.

Related Videos
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
© 2024 MJH Life Sciences

All rights reserved.